Literature DB >> 35608698

Endoscopic findings do not predict per-oral pyloromyotomy (POP) response.

Kathryn Schwalbe1, Caitlin Finelli2, Soon Moon2, Hannah Niehaus2, Abhiram Kondajji2, Chao Tu3, Alisan Fathalizadeh4, Matthew Kroh5, Matthew Allemang2.   

Abstract

INTRODUCTION: Gastroparesis is a life-altering diagnosis caused by the stomach's inability to function in the absence of a mechanical obstruction. The primary causes are idiopathic, diabetic, and postoperative. Our first-line treatment for medical refractory gastroparesis is the endoscopic per-oral pyloromyotomy (POP) procedure. Predicting clinical response cost effectively remains elusive.
METHODS: All patients who underwent a POP procedure at our institution by a single surgical endoscopist from January 1, 2019 to June 30, 2020 were retrospectively reviewed. All endoscopic data were prospectively collected. The patients were followed by a survey including the Gastroparesis Cardinal Symptom Index (GCSI) and other relevant postoperative measures. The primary endpoint was clinical response defined as ≥ 1.0 decrease in the GCSI from preoperative to the time of survey. Secondary outcome was normalization of the gastric emptying study (GES).
RESULTS: Our patient population is 85% female and has an average age of 44.8 years. The diagnosis of gastroparesis is 71% iatrogenic, 19% postoperative, and 10% diabetic. On endoscopy, 30% had bile in the stomach and 65% had any degree of pylorospasm. The primary outcome measure of clinical response was 39% at an average of 697 ± 151 days post-POP, but 66% of patients attested to an improvement in their symptoms. Of 68 postoperative gastric emptying studies 50% normalized at an average of 145 ± 98 days. Following univariate and multivariate analyses of preoperative data and endoscopic findings, there were no significant predictors of clinical response. A preoperative GCSI ≥ 2.6 trends toward significance (OR 6.87, p = 0.058).
CONCLUSION: Endoscopic findings at the time of POP do not correlate with clinical response. The GCSI model currently used to measure clinical response may not accurately capture the full clinical picture. The long-term durability of endoscopic myotomy to treat medical refractory gastroparesis needs to be studied further to improve patient selection.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Dysmotility; Gastric per-oral endoscopic myotomy; Gastroparesis; Per-oral pyloromyotomy

Year:  2022        PMID: 35608698     DOI: 10.1007/s00464-022-09321-8

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  19 in total

Review 1.  Epidemiology and Pathophysiology of Gastroparesis.

Authors:  Baha Moshiree; Michael Potter; Nicholas J Talley
Journal:  Gastrointest Endosc Clin N Am       Date:  2019-01

2.  Gastric peroral endoscopic myotomy for refractory gastroparesis: first human endoscopic pyloromyotomy (with video).

Authors:  Mouen A Khashab; Ellen Stein; John O Clarke; Payal Saxena; Vivek Kumbhari; Bani Chander Roland; Anthony N Kalloo; Stavros Stavropoulos; Pankaj Pasricha; Haruhiro Inoue
Journal:  Gastrointest Endosc       Date:  2013-11       Impact factor: 9.427

Review 3.  Surgical Management for Gastroparesis.

Authors:  Ahmed M Zihni; Christy M Dunst; Lee L Swanström
Journal:  Gastrointest Endosc Clin N Am       Date:  2018-09-22

4.  Gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis: a prospective single-center experience with mid-term follow-up (with video).

Authors:  Lennon Gregor; John Wo; John DeWitt; Brandon Yim; Robert Siwiec; Thomas Nowak; Martha Mendez; Anita Gupta; Destenee Dickason; Sarah Stainko; Mohammad Al-Haddad
Journal:  Gastrointest Endosc       Date:  2020-12-26       Impact factor: 9.427

5.  Manometric evaluation of the interdigestive antroduodenal motility in subjects with fasting bile reflux, with and without antral gastritis.

Authors:  P A Testoni; L Fanti; F Bagnolo; S Passaretti; M Guslandi; E Masci; A Tittobello
Journal:  Gut       Date:  1989-04       Impact factor: 23.059

6.  Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis.

Authors:  Mohamed M Abdelfatah; Alan Noll; Neil Kapil; Rushikesh Shah; Lianyong Li; Rosemary Nustas; Baiwen Li; Hui Luo; Huimin Chen; Liang Xia; Parit Mekaroonkamol; Nikrad Shahnavaz; Steven Keilin; Field Willingham; Jennifer Christie; Qiang Cai
Journal:  Clin Gastroenterol Hepatol       Date:  2020-05-22       Impact factor: 11.382

7.  Assessing pyloric sphincter pathophysiology using EndoFLIP in patients with gastroparesis.

Authors:  Z Malik; A Sankineni; H P Parkman
Journal:  Neurogastroenterol Motil       Date:  2015-02-24       Impact factor: 3.598

8.  Evaluation of the pylorus with concurrent intraluminal pressure and EndoFLIP in patients with nausea and vomiting.

Authors:  W J Snape; M S Lin; N Agarwal; R E Shaw
Journal:  Neurogastroenterol Motil       Date:  2016-01-27       Impact factor: 3.598

9.  Laparoscopic pyloroplasty versus endoscopic per-oral pyloromyotomy for the treatment of gastroparesis.

Authors:  Joshua P Landreneau; Andrew T Strong; Kevin El-Hayek; Chao Tu; James Villamere; Jeffrey L Ponsky; Matthew D Kroh; John H Rodriguez
Journal:  Surg Endosc       Date:  2018-07-17       Impact factor: 4.584

Review 10.  Outcomes of per oral endoscopic pyloromyotomy in gastroparesis worldwide.

Authors:  Parit Mekaroonkamol; Rushikesh Shah; Qiang Cai
Journal:  World J Gastroenterol       Date:  2019-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.